- 中国精品科技期刊
- 中国高校百佳科技期刊
- 中国中文核心期刊
- 中国科学引文数据库核心期刊
| Citation: |
XU Jingwen, JIANG Huici, CHEN Ximin, DING Guipeng. Advances in antibody drugs for treatment of melanoma[J]. Journal of China Pharmaceutical University, 2014, 45(3): 259-266. DOI: 10.11665/j.issn.1000-5048.20140302
|
| [1] |
Rainmakers MI,Rozati S,Goldinger SM,et al.Melanoma immunotherapy:historical precedents,recent successes and future prospects[J].Immunotherapy,2013,5(2):169-182.
|
| [2] |
Addeo A,Rinaldi CR.Treatment with ipilimumab:a case report of complete response in a metastatic malignant melanoma patient[J].Case Rep Oncol,2013,6(2):285-288.
|
| [3] |
Committee of Experts of Chinese Society of Clinical Oncology.Guidelines for Diagnosis and Treatment of Melanoma in China(中国黑色素瘤诊治指南)[M].Beijing:People′s Medical Publishing House,2013:1.
|
| [4] |
Balch CM,Gershenwald JE,Soong SJ,et al.Final version of 2009 AJCC melanoma staging and classification[J].J Clin Oncol,2009,27(36):6 199-6 206.
|
| [5] |
Matin RN,Chikh A,Chong SL,et al.p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis[J].J Exp Med,2013,10(3):581-603.
|
| [6] |
Chen J,Shao R,Zhang XD,et al.Applications of nanotechnology for melanoma treatment,diagnosis,and theranostics[J].Int J Nanomedicine,2013,8:2 677-2 688.
|
| [7] |
Teimouri F,Nikfar S,Abdollahi M.Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma:a meta-analysis consisting of 1314 patients[J].Melanoma Res,2013.[Epub ahead of print].
|
| [8] |
Faje AT,Nachtigall L,Wexler D,et al.Central diabetes insipidus:a previously unreported side effect of temozolomide[J].J Clin Endocrinol Metab,2013,98(10):3 926-3 931.
|
| [9] |
Luke JJ,Hodi FS.Ipilimumab,vemurafenib,dabrafenib,and trametinib:synergistic competitors in the clinical management of BRAF mutant malignant melanoma[J].Oncologist,2013,18(6):717-725.
|
| [10] |
Nelson B.A power surge for cancer immunotherapy:antibodies,vaccines,and engineered T cells fuel new optimism[J].Cancer Cytopathol,2014,122(1):1-2.
|
| [11] |
Scott AM,Wolchok JD,Old LJ.Antibody therapy of cancer[J].Nat Rev Cancer,2012,12(4):278-287.
|
| [12] |
Kasahara H,Kakimoto T,Saito H,et al.Successful treatment with rituximab for angioimmunoblastic T-cell lymphoma[J].Leuk Res Rep,2013,2(1):36-38.
|
| [13] |
Cragg MS,Walshe CA,Ivanov AO,et al.The biology of CD20 and its potential as a target for mAb therapy[J].Curr Dir Autoimmun,2005,8:140-174.
|
| [14] |
Maloney DG.Anti-CD20 antibody therapy for B-cell lymphomas[J].N Engl J Med,2012,366(21):2 008-2 016.
|
| [15] |
Fedele P,Orlando L,Schiavone P,et al.Clinical outcomes and cardiac safety of continuous antiHer2 therapy in c-erbB2-positive metastatic breast cancer patients[J].J Chemother,2013,25(6):369-375.
|
| [16] |
Zurawska U,Baribeau DA,Giilck S,et al.Outcomes of her2-positive early-stage breast cancer in the trastuzumab era:a population-based study of Canadian patients[J].Curr Oncol,2013,20(6):e539-545.
|
| [17] |
Bendell JC,Tournigand C,Swieboda-Sadlej A,et al.Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer:a randomized phase II study[J].Clin Colorectal Cancer,2013,12(4):239-247.
|
| [18] |
Zito CR,Kluger HM.Immunotherapy for metastatic melanoma[J].J Cell Biochem,2012,113(3):725-734.
|
| [19] |
Sapoznik S,Hammer O,Ortenberg R,et al.Novel anti-melanoma immunotherapies:disarming tumor escape mechanisms[J].Clin Dev Immunol,2012,2012:818214.
|
| [20] |
Graziani G,Tentori L,Navarra P.Ipilimumab:a novel immunostimulatory monoclonal antibody for the treatment of cancer[J].Pharmacol Res,2012,65(1):9-22.
|
| [21] |
Finn L,Markovic SN,Joseph RW.Therapy for metastatic melanoma:the p???爬慰湲摥潳浥楮穴攬摡?捤氠楦湵楴捵慲汥?瑊牝椮愼汩￣捂潍浃瀠慍牥楤渼术?琾爬攲洰攱氲椬洼畢派愱戰?眯楢琾栺′猳琮愼湢摲愯爾摛?漲晝?捌慩牰敳?据栠故浊漬瑄桲敡牫慥瀠祃?椮湉?灩慬瑩業敵湭瑡獢?睡楮琠桡?慴摩瘭慃湔捌敁搭?洠敡汮慴湩潢浯慤孹?嵦??椠????汳楴湡?佩湣挠潭汥??楮???せ????扩?????戠??????ㄠ???监土??戬爲??嬱??嵢￣?愷氼愯扢爾?′???漶爠爹愵????漹渶猲愮琼瑢楲????椳?攠瑍?慫汥??楁??呐牨敡浮攠汇楑洬畁浴慴扩?映潐爬?灩愾瑥楴攠湡瑬猼?睩椾琮桔?捭桯敲洠潲瑥桧敲牥慳灳祩??爠敡獮楤猠瑡慵湴瑯?慭摭癵慮湩捴敹搠?浮愠汰楡杴湩慥湮瑴?洠整獲潥瑡桴敥汤椠潷浩慴?愠湣?潴灯整湯?汩慣戠敔氠?獹業湰杨汯散?慴牥洭?灳桳慯獣敩???瑤爠楡慮汴孩?嵥??椴??慬湯捣敫瑡?佥渠捡潮汤??楮???ぬ????扮?????扰???????????????????戼物??孮??嵓??捧?敏牮浣潯瑬琼?????琰欰椵測猼????值????愱猲?愺?瀠漰琰攵渭琱椠愰氱?琮愼牢杲支琾?椲渴?挠慗湯捬散牨?瑫栠敊牄愬灎祥孹?嵳??椬??慮湥捴整牥??攬搼??楥???ぬ????戮????扩??????????????扡牰??孩??嵰?呴潩灥慮汴楳愠湷?却???牲慥歴敲????偤愠牡摤潶污汮????呭慥牬条敮瑯業湡机?琠桲敡?偤??????????偢?????灩慮瑤栬睭慵祬?瑩潣?慮捴瑲楥瘬慰瑨敡?慥渠琲椬?瑯畳浥漭牲?楮浧浩畮湧椠瑳祴孵?嵹??楝??畩爾牌?佮灣楥湴??浮浣畯湬漼氯??椬??㈱??监??戱?监???戨??呼??特???名?监??戯爾??嬵??崠?呯潬灣慨汯楫愠湊?匬???潩搠楆??南??牥慲栠浊敓爬??刾??椠?敬琼?慩氾??楥??卬慯晰敭瑥祮?愠捯瑦椠癩楰瑩祬?慭湵摭?楢洺洠畡渠敮?捶潥牬爠敩汭慭瑵敮獯?潨晥?慡湰瑥極?偩????慰湲瑯楡扣潨搠祦?楲渠?捨慥渠捴敲牥孡?嵭??楴?乯??湡杤汶????敤搠??楬???ね????戮??????戠????????????监??????戱爳??孢??崠′圹漱氼振桢漾欺?????氼畢杲支爾????愠汈汥慲桳慨渠?????楄?敹琠?慊氬??楷??乲楬癹漠汊甬洼慩戾?灴氠畡獬?椯灩椾氮楁洠異浨慡扳?椠湉?愠摭癵慬湴捩散摥?浴敥汲愠湳潴浵慤孹?嵯??楩?乩??湭杵汭????敩摴??楯???ど????扴??????扢?????ㄠ????????扴牨??孡??崭?卡穩湶潥氠???偩潥睮摴敳爠汷祩????卤浶楡瑮档?????楬?敮瑯?慡汛??椮??匾慉普敶瑥祳?愠湎摥?愠湄瑲極瑧畳洼漯物￣愬挲琰椱瘱椬琼祢￣漲昹?戯楢眾攨攳欩氺礴???場???????渾瑛椲?偝??????卆????????体乊伬??????楯湴?瀠慄瑆椬攼湩琾獥?眠楡瑬格?慩搾瘮慉湭捰敲摯?牥敤映牳慵捲瑶潩牶祡?洠慷汩楴杨渠慩湰捩楬敩獭孵?嵡??楩????汴楩湥?佴湳挠潷汩??椠???ち?ぴ??扩?㈠???扡??卭畡灛灊汝??慩戾獎琠牅???????扥牤??孩??崲‰圱攰戬攼牢￣??匳??畢搾挨核愩携欷愱爱?刷刲?央甼????楛?攸瑝?慒汯??楲??千愬晔敨瑯祭?敳映晌椬捂慯据祤?慲湥摮?扯椠潉洬愼物款敥牴猠?潬昼?湩椾瘮潉汰畩浬慩扭?睭楡瑢栠?癬慵捳挠楤湡散?楲湢?楺灩楮汥椠浦畯浲愠扰?牥敶晩牯慵捳瑬潹爠祵?潴牲?湡慴楥癤攠?浥整污慳湴潡浴慩季?嵭??楡????汛楊湝?似湩挾潎氠??楧????????戯?????戱?????????????′?ㄩ???戵爱??嬲??崲??愼浢楲搯￣佛?刹潝戠敒物瑢????愮甠摃????楣?敬琠?慥汶??楯??卥慮晴攠瑯祦?慴湨摥?瑡畮浴潩爭?牔敌獁瀭漴渠獡敮獴?睢楯瑤桹?汔慲浥扭牥潬汩業穵畭浡慢扛?慝渮琼楩?偓????椠湏?浣敯汬愼港潩派愬嬲?崱??椼?举″?渼术汢￣?‵?攺搴??椭??名?????戾??????扡?????ㄠ????????扩牡??嬬??嵳?坡敮猠瑊椬渼??剥??桡畬???娾栮慐湨条????椯?敉琠?慲汩??椠??匠慴晲敥瑭祥?慩湭摵?慡换琠楩癮椠瑰祡?潩晥?側?ㄠ?扩汴潨挠歭慥摴敡?扴祡?灩楣搠業汥楬穡畮浯慭扡?楊湝?挼潩派扊椠湃慬瑩楮漠湏?督楯瑬格?物椾琬甲砰椰洹愬戼?椾渲?瀼愯瑢椾攨渷琩猺?眠椰琷栵?爱攠氰愸瀱献攼摢?是漾汛氳椱捝甠汋慩牲?汷祯浯灤栠潊浍愬?慯?獩楧湡杮氠敐?杈牥潲畳灥?漠灐攬渼?氾慥扴攠污?瀼栯慩猾攮???瑳牥椠慉汉嬠?嵲??楬??慦渠捴敲瑥?佥湬捩潭汵??楢????????戲?????戠????????????扨爠??孶??嵣??攠牲扥獦瑲?剣却??潹爠摯潲渠??卬??楳湥敤????楡??敭瑡?慊汝??楩????獮琠畃摡祮?潥晲??健????????愱渰?攼湢朾椱渶攼支牢放搨″倩?????愲渭琱椠戰漴搸礮?楢湲?瀾慛琳椲敝渠瑒獩?睡楳琠桁?汋潥捦慦汯汲祤?慒搬癍慡湲捳敨摡?潬爠?流攬琼慩猾瑥慴琠楡捬?琯畩派漮牐獨孡?嵥??椀????氀椀渀?伀渀挀漀氀??椀??? ????戀?????戀??匀甀瀀瀀氀??愀戀猀琀爀?? ??戀爀??嬀??崀??愀洀椀搀?伀?匀漀猀洀愀渀????愀眀爀攀渀挀攀?????椀?攀琀?愀氀??椀???氀椀渀椀挀愀氀?愀挀琀椀瘀椀琀礀?猀愀昀攀琀礀?愀渀搀?戀椀漀洀愀爀欀攀爀猀?漀昀??倀????? ??愀渀?攀渀最椀渀攀攀爀攀搀?倀?????愀渀琀椀戀漀搀礀?椀渀?瀀愀琀椀攀渀琀猀?眀椀琀栀?洀攀琀愀猀琀愀琀椀挀?洀攀氀愀渀漀洀愀嬀?崀??椀????氀椀渀?伀渀挀漀氀??椀??? ????戀?????戀??匀甀瀀瀀氀??愀戀猀琀爀?? ? ??戀爀??嬀??崀??爀椀最渀漀氀?嘀倀?伀氀攀渀挀欀椀?吀?刀攀氀攀欀愀爀????椀?攀琀?愀氀??椀????瀀栀愀猀攀???琀爀椀愀氀?漀昀?戀攀瘀愀挀椀稀甀洀愀戀?愀渀搀?栀椀最栀?搀漀猀攀?椀渀琀攀爀昀攀爀漀渀?愀氀瀀栀愀????椀渀?洀攀琀愀猀琀愀琀椀挀?洀攀氀愀渀漀洀愀嬀?崀??椀????洀洀甀渀漀琀栀攀爀??椀??? ????戀?????戀?????? ???????戀爀??嬀??崀?瘀漀渀??漀漀猀?刀?匀攀椀昀攀爀琀???匀椀洀挀漀挀欀????椀?攀琀?愀氀??椀???椀爀猀琀?氀椀渀攀?琀攀洀漀稀漀氀漀洀椀搀攀?挀漀洀戀椀渀攀搀?眀椀琀栀?戀攀瘀愀挀椀稀甀洀愀戀?椀渀?洀攀琀愀猀琀愀琀椀挀?洀攀氀愀渀漀洀愀?愀?洀甀氀琀椀挀攀渀琀爀攀?瀀栀愀猀攀????琀爀椀愀氀?匀????? ? ??嬀?崀??椀??渀渀?伀渀挀漀氀??椀??? ????戀?????戀??????????????戀爀??嬀??崀?匀氀椀渀最氀甀昀昀?????爀?倀攀琀爀漀渀椀??刀??漀氀栀漀攀欀??刀??椀?攀琀?愀氀??椀???氀椀渀椀挀愀氀?愀挀琀椀瘀椀琀礀?愀渀搀?猀愀昀攀琀礀?漀昀?挀漀洀戀椀渀愀琀椀漀渀?琀栀攀爀愀瀀礀?眀椀琀栀?琀攀洀猀椀爀漀氀椀洀甀猀?愀渀搀?戀攀瘀愀挀椀稀甀洀愀戀?昀漀爀?愀搀瘀愀渀挀攀搀?洀攀氀愀渀漀洀愀?愀?瀀栀愀猀攀????琀爀椀愀氀??吀?倀???? ??攀氀???嬀?崀??椀??氀椀渀??愀渀挀攀爀?刀攀猀??椀??? ????戀?????戀???????????????? ??戀爀??嬀??崀?匀稀渀漀氀????漀搀椀??匀??愀爀最漀氀椀渀????椀?攀琀?愀氀??椀??倀栀愀猀攀???猀琀甀搀礀?漀昀???匀????????愀?昀甀氀氀礀?栀甀洀愀渀?愀渀琀椀???????愀最漀渀椀猀琀?洀漀渀漀挀氀漀渀愀氀?愀渀琀椀戀漀搀礀?椀渀?瀀愀琀椀攀渀琀猀?瀀琀猀?眀椀琀栀?愀搀瘀愀渀挀攀搀?挀愀渀挀攀爀????嬀?崀??椀????氀椀渀?伀渀挀漀氀??椀??? ???戀?????戀??匀甀瀀瀀氀??愀戀猀琀爀?? ???戀爀??嬀??崀??椀???圀愀渀最???堀椀愀渀最?????椀?攀琀?愀氀??椀???漀渀漀挀氀漀渀愀氀?愀渀琀椀戀漀搀椀攀猀?琀愀爀最攀琀椀渀最?戀愀猀椀挀?昀椀戀爀漀戀氀愀猀琀?最爀漀眀琀栀?昀愀挀琀漀爀?椀渀栀椀戀椀琀?琀栀攀?最爀漀眀琀栀?漀昀?????洀攀氀愀渀漀洀愀?椀??椀渀?瘀椀瘀漀??椀??愀渀搀??椀?椀渀?瘀椀琀爀漀??椀?嬀?崀??椀?伀渀挀漀氀?刀攀瀀??椀??? ? ??戀?????戀?????????????
|
| [1] | WANG Zhijie, LIAO Xiaotong, GUO Xia, CHEN Jianjun. New strategies for targeting PD-1/PD-L1: degraders, bifunctional molecules and covalent inhibitors[J]. Journal of China Pharmaceutical University, 2024, 55(1): 5-14. DOI: 10.11665/j.issn.1000-5048.2023112702 |
| [2] | SHAO Shishuai, DUAN Shukang, TIAN Hong, YAO Wenbing, GAO Xiangdong. Design and antitumor activity of programmed cell death ligand 1 epitope peptide vaccine[J]. Journal of China Pharmaceutical University, 2023, 54(2): 245-254. DOI: 10.11665/j.issn.1000-5048.2023022803 |
| [3] | XU Shuyi, LI Yaxian, HU Hai, ZHANG Li, BIAN Yanlin, ZHU Jianwei, WU Mingyuan. Purification and activity of anti-PD-L1&CXCR4 bispecific nanobody[J]. Journal of China Pharmaceutical University, 2021, 52(5): 622-629. DOI: 10.11665/j.issn.1000-5048.20210516 |
| [4] | CHEN Hongmei, KANG Yanliang, LIU Li, YAO Wenbing, TIAN Hong. Effects of different immunogenic amino acids in PD-L1 vaccine on the differentiation of T cell subsets[J]. Journal of China Pharmaceutical University, 2020, 51(3): 349-356. DOI: 10.11665/j.issn.1000-5048.20200313 |
| [5] | WAN Nanyan, JIANG Cuihua, GAO Meng, ZHANG Jian, YIN Zhiqi, PAN Ke. Paeoniflorin inhibits programmed cell death-1-ligand 1 expression in HepG2 cells by regulating JAK/STAT3 signal pathway[J]. Journal of China Pharmaceutical University, 2019, 50(2): 213-221. DOI: 10.11665/j.issn.1000-5048.20190213 |
| [6] | TIAN Jiping, ZHANG Jian, ZHOU Jinpei, ZHANG Huibin. Advances in small molecule inhibitors of PD-1/PD-L1 immune checkpoint pathway[J]. Journal of China Pharmaceutical University, 2019, 50(1): 1-10. DOI: 10.11665/j.issn.1000-5048.20190101 |
| [7] | PAN Jiajia, JIA Xiaoqing, HUANG Gang, ZHANG Yubin. PD-1/PD-Ls signaling pathway and the application of anti-PD-1/PD-Ls antibodies in cancer therapy[J]. Journal of China Pharmaceutical University, 2016, 47(1): 9-18. DOI: 10.11665/j.issn.1000-5048.20160102 |
| [8] | LU Shiping, JIN Liang, WU Jie. Clinical development of type 1 diabetes vaccine[J]. Journal of China Pharmaceutical University, 2014, 45(6): 625-632. DOI: 10.11665/j.issn.1000-5048.20140603 |
| [9] | MIAO You-pan, LI Ai-xiu, LIU Tao, WU Ke-zhu. Molecular designing strategies of anti-drug-resistant HIV-1 protease inhibitors[J]. Journal of China Pharmaceutical University, 2009, 40(3): 279-283. |
| [10] | Kong Lingyi, Li Yi, Min Zhida. Study on Analysis of Pd Ia in Peucedanum Praerupto rum and Pd C I in Peucedanum Decursivum by RP HPLC[J]. Journal of China Pharmaceutical University, 1996, (4). |
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Total visits：292727
DownLoad: